Viewing Study NCT03047395


Ignite Creation Date: 2025-12-24 @ 1:13 PM
Ignite Modification Date: 2025-12-29 @ 10:14 PM
Study NCT ID: NCT03047395
Status: COMPLETED
Last Update Posted: 2024-12-11
First Post: 2017-02-07
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )
Sponsor: AbbVie
Organization: